Islet grafting and imaging in a bioengineered intramuscular space

Transplantation

Volumn 88, Issue 9, 2009, Pages 1065-1074

  Witkowski, Piotr ^a,b   Sondermeijer, Hugo ^a   Hardy, Mark A ^a   Woodland, David C ^a   Lee, Keagan ^a   Bhagat, Govind ^a   Witkowski, Kajetan ^a   See, Fiona ^a   Rana, Abbas ^a   Maffei, Antonella ^c   Itescu, Silviu ^a   Harris, Paul E ^a  

^a Howard Hughes Medical Institute   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

Author keywords

Bioengineering.; Imaging; Islet transplantation

Indexed keywords

DIHYDROTETRABENAZINE; GLUCOSE; INSULIN; PLATELET DERIVED GROWTH FACTOR; TISSUE SCAFFOLD; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCOMPATIBILITY; BIOENGINEERING; CONTROLLED STUDY; ENGRAFTMENT; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HISTOPATHOLOGY; HYPERGLYCEMIA; IMAGING; INTRAMUSCULAR PANCREAS ISLET TRANSPLANTATION; MALE; METABOLISM; MUSCLE; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; SURVIVAL TIME;

ANIMALS; BIOMEDICAL ENGINEERING; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE TOLERANCE TEST; INSULIN; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MUSCLE, SKELETAL; NEOVASCULARIZATION, PHYSIOLOGIC; PORTAL SYSTEM; POSITRON-EMISSION TOMOGRAPHY; RATS; RATS, INBRED LEW; RATS, SPRAGUE-DAWLEY; TRANSPLANTATION, ISOGENEIC; TREATMENT OUTCOME;

EID: 72949107090     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181ba2e87     Document Type: Article

References (49)

1. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free im-munosuppressive regimen. N Engl J Med 2000; 343: 230.
2. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54: 2060.
3. Hering BJ, Kandaswamy R, Ansite JD, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 2005; 293: 830.
4. Narang AS, Mahato RI. Biological and biomaterial approaches for improved islet transplantation. Pharmacol Rev 2006; 58: 194.
5. Robertson RP. Islet transplantation as a treatment for diabetes-A work in progress. N Engl J Med 2004; 350: 694.
6. Desai NM, Goss JA, Deng S, et al. Elevated portal vein drug levels of sirolimus and tacrolimus in islet transplant recipients: Local immuno-suppression or islet toxicity? Transplantation 2003; 76: 1623.
7. Shapiro AM, Gallant H, Hao E, et al. Portal vein immunosuppressant levels and islet graft toxicity. Transplant Proc 1998; 30: 641.
8. Bennet W, Sundberg B, Groth CG, et al. Incompatibility between human blood and isolated islets of Langerhans: A finding with implications for clinical intraportal islet transplantation? Diabetes 1999; 48: 1907.
9. Dufour JM, Rajotte RV, Zimmerman M, et al. Development of an ec-topic site for islet transplantation, using biodegradable scaffolds. Tissue Eng 2005; 11: 1323.
10. Pileggi A, Cobianchi L, Inverardi L, et al. Overcoming the challenges now limiting islet transplantation: A sequential, integrated approach. Ann N Y Acad Sci 2006; 1079: 383.
11. Bucher P, Mathe Z, Bosco D, et al. Morbidity associated with intrapor-tal islet transplantation. Transplant Proc 2004; 36: 1119.
12. Shapiro AM, Hao EG, Lakey JR, et al. Novel approaches toward early diagnosis of islet allograft rejection. Transplantation 2001; 71: 1709.
13. Saisho Y, Harris PE, Butler AE, et al. Relationship between pancreatic vesicular monoamine transporter 2 (VMAT2) and insulin expression in human pancreas. J Mol Histol 2008; 39: 543.
14. Simpson NR, Souza F, Witkowski P, et al. Visualizing pancreatic beta-cell mass with [11C]DTBZ. Nucl Med Biol 2006; 33: 855.
15. Goland R, Freeby M, Parsey R, et al. 11C-Dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. J Nucl Med 2009; 50: 382.
16. Prokop A, Wang TG. Purification of polymers used for fabrication of an immunoisolation barrier. Ann N Y Acad Sci 1997; 831: 223.
17. Rowley JA, Madlambayan G, Mooney DJ. Alginate hydrogels as synthetic extracellular matrix materials. Biomaterials 1999; 20: 45.
18. Kantlehner M, Schaffner P, Finsinger D, et al. Surface coating with cyclic RGD peptides stimulates osteoblast adhesion and proliferation as well as bone formation. Chembiochem 2000; 1: 107.
19. Ali A, Garrovillo M, Jin MX, et al. Major histocompatibility complex class I peptide-pulsed host dendritic cells induce antigen-specific acquired thymic tolerance to islet cells. Transplantation 2000; 69: 221.
20. Barnett MJ, McGhee-Wilson D, Shapiro AM, et al. Variation in human islet viability based on different membrane integrity stains. Cell Transplant 2004; 13: 481.
21. Eizirik DL, Korbutt GS, Hellerstrom C. Prolonged exposure of human pancreatic islets to high glucose concentrations in vitro impairs the beta-cell function. J Clin Invest 1992; 90: 1263.
22. Kilbourn M, Lee L, Vander Borght T, et al. Binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific. Eur J Pharmacol 1995; 278: 249.
23. Souza F, Simpson N, Raffo A, et al. Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat model. J Clin Invest 2006; 116: 1506.
24. Logan J. Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl Med Biol 2000; 27: 661.
25. Freeby M, Goland R, Ichise M, et al. VMAT2 quantitation by PET as a biomarker for beta-cell massinhealth and disease.Diabetes Obes Metab 2008; 10(suppl 4): 98.
26. Weber CJ, Hardy MA, Pi-Sunyer F, et al. Tissue culture preservation and intramuscular transplantation of pancreatic islets. Surgery 1978; 84: 166.
27. Axen KV, Pi-Sunyer FX. Long-term reversal of streptozotocin-induced diabetes in rats by intramuscular islet implantation. Transplantation 1981; 31: 439.
28. Juang JH, Hsu BR, Kuo CH. Islet transplantation at subcutaneous and intramuscular sites. Transplant Proc 2005; 37: 3479.
29. Simeonovic CJ, Dhall DP, Wilson JD, et al. A comparative study of transplant sites for endocrine tissue transplantation in the pig. Aust J Exp Biol Med Sci 1986; 64(pt 1): 37.
30. Richardson TP, Peters MC, Ennett AB, et al. Polymeric system for dual growth factor delivery. Nat Biotechnol 2001; 19: 1029.
31. Hersel U, Dahmen C, Kessler H. RGD modified polymers: Biomaterials for stimulated cell adhesion and beyond. Biomaterials 2003; 24: 4385.
32. Pierschbacher MD, Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 1984; 309: 30.
33. Wang RN, RosenbergL.Maintenanceofbeta-cell function and survival following islet isolation requires re-establishment of the islet-matrix relationship. J Endocrinol 1999; 163: 181.
34. Kedem A, Perets A, Gamlieli-Bonshtein I, et al. Vascular endothelial growth factor-releasing scaffolds enhance vascularization and engraftment of hepatocytes transplanted on liver lobes. Tissue Eng 2005; 11: 715.
35. Klock G, Pfeffermann A, Ryser C, et al. Biocompatibility of mannu-ronic acid-rich alginates. Biomaterials 1997; 18: 707.
36. de Vos P, Faas MM, Strand B, et al. Alginate-based microcapsules for immunoisolation of pancreatic islets. Biomaterials 2006; 27: 5603.
37. Dainty AL, Goulding KH, Robinson PK, et al. Stability of alginate-immobilized algal cells. Biotechnol Bioeng 1986; 28: 210.
38. Lanza RP, Jackson R, Sullivan A, et al. Xenotransplantation of cells using biodegradable microcapsules. Transplantation 1999; 67: 1105.
39. Chen RR, Silva EA, Yuen WW, et al. Spatio-temporal VEGF and PDGF delivery patterns blood vessel formation and maturation. Pharm Res 2007; 24: 258.
40. Kidszun A, Schneider D, Erb D, et al. Isolated pancreatic islets in three-dimensional matrices are responsive to stimulators and inhibitors of angiogenesis. Cell Transplant 2006; 15: 489.
41. Nillesen ST, Geutjes PJ, Wismans R, et al. Increased angiogenesis and blood vessel maturation in acellular collagen-heparin scaffolds containing both FGF2 and VEGF. Biomaterials 2007; 28: 1123.
42. Vasir B, Aiello LP, Yoon KH, et al. Hypoxia induces vascular endothe-lial growth factor gene and protein expression in cultured rat islet cells. Diabetes 1998; 47: 1894.
43. Danielsson C, Ruault S, Basset-Dardare A, et al. Modified collagen fleece, a scaffold for transplantation of human bladder smooth muscle cells. Biomaterials 2006; 27: 1054.
44. Elisseeff J, Ferran A, Hwang S, et al. The role of biomaterials instem cell differentiation: Applications in the musculoskeletal system. Stem Cells Dev 2006; 15: 295.
45. Balamurugan AN, Gu Y, Tabata Y, et al. Bioartificial pancreas transplantation at prevascularized intermuscular space: Effect of angiogen-esis induction on islet survival. Pancreas 2003; 26: 279.
46. Gu Y, Tabata Y, Kawakami Y, et al. Development of a new method to induce angiogenesis at subcutaneous site of streptozotocin-induced diabetic rats for islet transplantation. Cell Transplant 2001; 10: 453.
47. Trivedi N, Steil GM, Colton CK, et al. Improved vascularization of planar membrane diffusion devices following continuous infusion of vascular endothelial growth factor. Cell Transplant 2000; 9: 115.
48. Pinkse GG, Bouwman WP, Jiawan-Lalai R, et al. Integrin signaling by RGD peptides and anti-beta1 antibodies confers resistancetoapoptosis in islets of Langerhans. Diabetes 2006; 55: 312.
49. Nir T, Melton DA, Dor Y. Recovery from diabetes in mice by beta cell regeneration. J Clin Invest 2007; 117: 2553.